CZC 25146

Pricing Availability   Qty
Description: Potent LRRK2 inhibitor
Chemical Name: N-[2-[[5-Fluoro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]phenyl]methanesulfonamide
Purity: ≥98% (HPLC)
Literature (1)

Biological Activity for CZC 25146

CZC 25146 is a potent LRRK2 inhibitor (IC50 values are 4.76 and 6.87 nM for for wild-type and G2019S mutant forms of LRRK2, respectively). Also inhibits PLK4, GAK, TNK1, CAMKK2 and PIP4K2. Attenuates mutant LRRK2-induced injury of cultured rodent and human neurons. Cell permeable.

Compound Libraries for CZC 25146

CZC 25146 is also offered as part of the Tocriscreen 2.0 Max and Tocriscreen Kinase Inhibitor Library. Find out more about compound libraries available from Tocris.

Technical Data for CZC 25146

M. Wt 488.54
Formula C22H25FN6O4S
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 1191911-26-8
PubChem ID 44252884
Smiles FC1=C(NC2=CC=CC=C2NS(C)(=O)=O)N=C(NC3=C(OC)C=C(N4CCOCC4)C=C3)N=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for CZC 25146

Solvent Max Conc. mg/mL Max Conc. mM
DMSO 48.85 100

Preparing Stock Solutions for CZC 25146

The following data is based on the product molecular weight 488.54. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.05 mL 10.23 mL 20.47 mL
5 mM 0.41 mL 2.05 mL 4.09 mL
10 mM 0.2 mL 1.02 mL 2.05 mL
50 mM 0.04 mL 0.2 mL 0.41 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets for CZC 25146

Certificate of Analysis / Product Datasheet
Select another batch:

References for CZC 25146

References are publications that support the biological activity of the product.

Ramsden et al (2011) Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem.Biol. 6 1021 PMID: 21812418

If you know of a relevant reference for CZC 25146, please let us know.

View Related Products by Target

View Related Products by Product Action

View all LRRK2 Inhibitors

Keywords: CZC 25146, CZC 25146 supplier, CZC25146, leucine-rich, repeat, kinase, 2, LRRK2, inhibitors, inhibits, potent, neuroprotective, neuronal, injury, parkinson's, parkinsons, 6071, Tocris Bioscience

Citations for CZC 25146

Citations are publications that use Tocris products.

Currently there are no citations for CZC 25146. Do you know of a great paper that uses CZC 25146 from Tocris? Please let us know.

Reviews for CZC 25146

There are currently no reviews for this product. Be the first to review CZC 25146 and earn rewards!

Have you used CZC 25146?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.